Navigation Links
DiaVacs's Immunotherapy Product for Treatment of Type 1 Diabetes Receives Orphan Drug Status Designation from the FDA
Date:1/6/2014

EDGEWATER, N.J., Jan. 6, 2014 /PRNewswire/ -- DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy. DV-0100 is proprietary, novel and safe. The therapy halt's the body's autoimmune reaction against the pancreatic islet cells which are responsible for producing insulin, thus allowing them to produce insulin normally and reversing the trajectory of the disease. Orphan designation qualifies DV-0100 for seven years of marketing exclusivity in the U.S. if the company is the first to obtain marketing approval for this product in T1DM and also qualifies the company for certain tax credits and waivers for prescription drug user fees.

"The granting of this orphan drug designation represents a key milestone for the company," commented Dr. Haro Hartounian, CEO of DiaVacs. "We are excited by the promise that DV-0100 showed in our Phase 1 clinical trial and look forward to assessing its therapeutic potential in the ongoing Phase 2 clinical trial for this indication."

The proprietary DiaVacs technology is derived from a deep understanding of the human immune system. The company has perfected the immunology and technology to take a patient's own dendritic cells (DC) from their blood, modify the cells through the use of small interfering oligonucleotides, and vaccinate the patient by injection of these modified cells under the skin with a small needle. The cells are absorbed, trafficked to the pancreatic lymph nodes, and thereby induce tolerance. This therapy has been shown to be safe and effective in animal models of T1DM, and evidenced no safety signals in human Phase 1 trials in patients with established type 1 diabetes for five years or longer. In some patients in our Phase 1 human trial, production of endogenous insulin was measured, even after 10 y
'/>"/>

SOURCE DiaVacs, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Immunotherapy Offers New Hope for Cancer Patients: One Man’s Alternative Cancer Treatment Journey
2. Leading Cancer Research Centers Team Up To Launch Biotech Startup Focused On Cancer Immunotherapy
3. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
4. FDA Review in Journal for ImmunoTherapy of Cancer Offers New Insights into Cancer Immunotherapy Product Development & Clinical Evaluation
5. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
6. Tuberculosis Immunotherapy Grant for Immunoxel Honibe Honey Lozenges
7. UroToday Launches New Prostate Cancer Focused Content Including Immunotherapy for Metastatic Castration-resistant Patients
8. Cancer Immunotherapy Expert Joins Pacific Meso Center Research Team
9. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
10. Star Scientific Receives a Warning Letter From the FDA Regarding Consumer Products
11. Marrone Bio Innovations Begins Production at Michigan Plant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Chelating Agents ... About Chelating Agent A chelating agent ... bonds with metal ions, thereby forming a metal-ion ... metal-ions have on chemical processes, formulations, and the ...
(Date:8/27/2014)... YORK , Aug. 27, 2014 Guggenheim ... Guggenheim Partners, today announced the hiring of veteran equity ... senior equity analyst. Mr. Butler will focus on the ... our team a wealth of experience and a broad ... Ferrarie , Senior Managing Director and Head of Equities ...
(Date:8/27/2014)...  ARCH Venture Partners, one of the largest ... of seed and early-stage advanced technology companies, today ... more than $400 million in subscriptions. ARCH Venture ... by more than $150 million. "The ... potential of our approach to finding and funding ...
(Date:8/27/2014)... White City, OR (PRWEB) August 27, 2014 ... Supply Report, “Consolidation continues to reshape the look and ... in nutrition. Consumer demand for higher-quality ingredients will push ... the North American market have experienced strong market growth ... and ethical attributes in their food and cosmetics to ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... 24, 2011 Champions Biotechnology, Inc. (OTC: CSBR) ... collaboration agreement with Cephalon, Inc. in which Champions ... proprietary chemical compounds, CEP-32496, an inhibitor of mutant ... provided by Cephalon to determine the activity or ...
... ValGenesis, Inc., an industry-leading provider of Validation ... availability of its industry-proven solution as an On-Demand ... MUSA,s Validated Cloud. ValGenesis On-Demand provides ... via the Internet through MUSA,s Validated Cloud on ...
... Medicine, Inc. (RBM), a leading provider of innovative biomarker ... ® , a powerful tool developed at the direction ... Through quantitative measurement of 101 cancer-related proteins, OncologyMAP ... biological pathways that could hold the key to understanding ...
Cached Biology Technology:Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 2Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 3Announcing ValGenesis On-Demand SaaS Solution 2Announcing ValGenesis On-Demand SaaS Solution 3Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development 2
(Date:8/27/2014)... to Europe based upon a proxy for impact have ... ,big data, approach to scientific research. , The researchers ... ranked the top 100 pathogens affecting humans and the ... they believe, will help governments across the continent plan ... including as a result of climate change, and for ...
(Date:8/27/2014)... . , Charcot-Marie-Tooth ... affecting the peripheral nervous system. Researchers from the Department ... Medicine and University Medical Centre Gttingen have discovered that ... with the disease. These cells enwrap the nerve fibres ... the rapid transfer of electrical impulses. If Schwann cells ...
(Date:8/27/2014)... York, NY (June, 2014) Outstanding basic research, ... and a dedication to patient care have earned ... Columbia University Medical Center (CUMC) and NewYork-Presbyterian Hospital ... from the National Cancer Institute (NCI). The grant ... two NCI-designated Comprehensive Cancer Centers in New York ...
Breaking Biology News(10 mins):Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Potential therapy for incurable Charcot-Marie-Tooth disease 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4
... as current directions and water temperature play a huge ... as they move from rivers and hit ocean waters ... findings inform restoration policies and practices focused on boosting ... findings, from ecologists at the Department of Energy,s Pacific ...
... The National Science Foundation (NSF), in cooperation with ... round of awards under a program that supports ... predictability, resiliency and sustainability of the natural and ... governance of the Arctic. Six projects ...
... international team of researchers says in a new paper ... realm more practical applications for dealing with the ... already exists as does much of the organizational structure, ... ranging from declining snowpack, to severe storms, to sea ...
Cached Biology News:Tracking young salmon's first moves in the ocean 2Tracking young salmon's first moves in the ocean 3Tracking young salmon's first moves in the ocean 4NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 2NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 3NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 4NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 5NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 6Researchers advocate for climate adaptation science 2Researchers advocate for climate adaptation science 3
Yersinia pestis...
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
Biology Products: